Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $2.20 is 62.96% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 2.45||$ 22.10|
|Low:||$ 2.20||$ 1.35|
Company Description (as filed with the SEC)
Versartis, Inc. is an endocrine-focused biopharmaceutical company that has been developing a novel long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency, or GHD, an orphan disease. The current standard of care for GHD is daily subcutaneous injections of rhGH. Despite the demonstrated benefits of rhGH therapy, published studies have shown that a majority of patients on a daily rhGH regimen, which requires up to 365 dosing events per year, are not fully compliant and fail to achieve the optimal treatment outcomes. Lack of compliance may be due to the burden of these frequent dosing events. We believe that a long-acting form of rhGH could address this significant unmet need. In our Phase 1a clinical trial in adults, somavaratan demonstrated a half-life at least thirty times longer than daily rhGH and tolerability profile consistent with that of marketed daily rhGH products. ... More ...
Nasdaq Official Price
Jun. 20, 2018
Jun. 20, 2018